-
MDA Ambassador Guest Blog: Built to Rise – Strength Forged Through Every Challenge
Darlene, who was diagnosed with spinal muscular atrophy (SMA) type 3 at age 19, just
-
Clinical Research Alert: At-Home Research Study in People with DM1
Sanguine Biosciences, a provider of at-home clinical research services, is seeking people living with myotonic dystrophy
-
How it feels to get recognition for my life as a caregiver
I’m no longer a young mom, but I was once. In fact, I was a
-
Watch: Capricor Therapeutics – Regulatory Update & Clinical Insights on Deramiocel for Duchenne Cardiomyopathy
Capricor Therapeutics recently joined PPMD for a community webinar on Tuesday, July 29, 2025 to
-
Duchenne MD gene-editing therapy nets orphan drug designation
An experimental gene editing therapy for Duchenne muscular dystrophy (DMD) being developed by Precision Biosciences
-
Community Voice: Why We Decided to Name MDA in Our Wills
Probably like you, recent years have altered our lives in ways both expected and completely
-
Behind the Drug: Risdiplam (Evrysdi) for SMA
Spinal muscular atrophy (SMA) is a rare genetic disease affecting 1 in 11,000 live births
-
A weekend trip with my family stirred up mixed feelings
Last summer, I wrote a column about my beach vacation with my family. It was
-
Your Voice Is Everything
When the Duchenne and Becker community speaks, the world listens — not just because of
-
Elevidys shipments for ambulatory DMD patients to resume
Sarepta Therapeutics will soon resume shipping Elevidys (delandistrogene moxeparvovec-rokl) for ambulatory Duchenne muscular dystrophy (DMD) patients,
